Authors
Latest:
Dr. Lin on the Limitations of Current Biomarkers in Prostate CancerDaniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.
Latest:
Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBCAnirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.
Latest:
Dr. Bergerot on Improved HRQoL With a Higher Starting Dose of Lenvatinib Plus Everolimus in RCCCristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.
Latest:
Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic MelanomaThe recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.
Latest:
EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S MutationExpert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.
Latest:
DNA Alterations and Selection of PARP Inhibitors in mCRPCExpert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
Latest:
Dr Nasioudis on the Use of SLNB in Metastatic Vulvar Squamous Cell CarcinomaDimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.
Latest:
Dr Marouf on the Efficacy of PD-L1 Inhibition in R/R Extranodal NK/T-cell LymphomaAmira Marouf, MD, PhD student, discusses the efficacy of PD-L1 inhibitors in relapsed/refractory extranodal natural killer/T-cell lymphoma.
Latest:
VIGH, VICC Establish Cancer Research Program in ZambiaVanderbilt University Medical Center and the University of Zambia are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia and to encourage U.S.-based researchers to engage in cancer research in low- and middle-income countries.
Latest:
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple MyelomaStudy establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.
Latest:
Dr. Dzienis on Use of Pembrolizumab with Carboplatin and Paclitaxel in HNSCCMarcin Dzienis, MD, discusses the use of pembrolizumab with carboplatin and paclitaxel in head and neck squamous cell carcinoma .
Latest:
BRONx-CAN Program Aims to Deliver the Best Cancer Treatments EarlyMontefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.
Latest:
Challenges in Managing Adverse Events and Unmet Needs in LeukemiaDr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.
Latest:
Dr. Tabrizian on the Rationale for Examining Cemiplimab in HCCParissa Tabrizian, MD, discusses the rationale for examining cemiplimab in hepatocellular carcinoma.
Latest:
Make Time for Your Own HealthAlthough graduate medical education at many hospitals includes provisions to ensure that trainees remain physically, emotionally, and mentally healthy, few residents and fellows make use of these resources.
Latest:
Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate CancerYung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.
Latest:
Ra-223 Displays Efficacy, Safety in mCRPC With Bone MetastasesRadium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.
Latest:
Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and BispecificsExpert perspective on advancements in cancer immunotherapy, including CAR-T cells, allogeneic strategies, and the role of bispecific antibodies.
Latest:
Dr Schinke on the Safety Profile of Talquetamab in Relapsed/Refractory MyelomaCarolina D. Schinke, MD, discusses the safety profile of talquetamab-tgvs in the phase 1/2 MonumenTAL-1 trial of patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Howard Sharp on the Importance of Racial and Ethnic Diversity in Pediatric Clinical TrialsKatianne M. Howard Sharp, PhD, discusses the importance of racial and ethnic diversity in clinical trials for pediatric patients with cancer.
Latest:
Differentiated Thyroid Cancer: Unmet Needs and Future DirectionsExperts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.
Latest:
Tulane Doctors Extend Their Reach in 2024The Tulane Transplant Institute offers comprehensive disease management for patients with end-stage organ disease of the kidney, liver, and pancreas.
Latest:
Dr. Elemento on Utilizing Circulating Tumor Cells to Assess Treatment Resistance in mCRPCOlivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.
Latest:
Dr. Ligresti on the Need for Screening in Pancreatic CancerRosario Ligresti, MD, discusses the need for screening in pancreatic cancer.
Latest:
Dr. Baskin on Mitigating Patient Concerns During the COVID-19 Pandemic in Prostate CancerMonica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.
Latest:
Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCNSangeetha Venugopal, MD, MS, discusses pivekimab sunirine (PVEK), a novel CD123-targeting antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN). PVEK showed promising response rates in treatment-naïve BPDCN patients in an early trial and was reasonably well-tolerated without concerning safety signals. Its FDA breakthrough therapy designation in relapsed/refractory BPDCN was based on phase 1 data suggesting good efficacy even after tagraxofusp (TAG). Early trials also support PVEK's potential in CD123+ acute myeloid leukemia, both as monotherapy and when combined with other agents like azacitidine and venetoclax.
Latest:
Dr Mehta on Radiation Oncology Innovations in Prostate CancerMinesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.
Latest:
Dr. Chu on Ongoing Efforts to Address Disparities in Lung CancerEdward Chu, MD, MMS, discusses ongoing efforts to address disparities in lung cancer at Montefiore and Albert Einstein College of Medicine.
Latest:
Advancement in Treating Uncommon EGFR Mutations: Key TakeawaysDiscover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.
